KNSA Share Price Performance
US$46.31
23.81 (105.82%)
17.1% undervalued intrinsic discount
US$55.88
Fair Value
Price US$46.31
AnalystConsensusTarget US$55.88
AnalystHighTarget US$62.00
AnalystLowTarget US$50.00
Fair ValueUS$55.88
Share Pricen/a
Kiniksa Pharmaceuticals International, plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 38 Fair Values set on narratives written by author
KNSA Community Narratives
AN
Fair Value US$55.88 17.1% undervalued intrinsic discount
Future Revenue Potential Will Advance With Deepening Market Penetration and Pipeline Progress
0users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AN
Fair Value US$62 25.3% undervalued intrinsic discount
ARCALYST Uptake And Pipeline Progress Will Expand Rare Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$50 7.4% undervalued intrinsic discount
Reliance On Flagship Therapy Will Intensify Competition But Spur Optimism
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Reliance On Flagship Therapy Will Intensify Competition But Spur Optimism
Key Takeaways Heavy dependence on a single flagship therapy heightens risk from competition and market shifts before pipeline diversification is achieved. Increasing payer scrutiny and regulatory hurdles threaten margins, pricing power, and timely realization of pipeline commercial value.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$50
7.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
21.07% p.a.
Profit Margin
8.47%
Future PE
53.73x
Price in 2029
US$61.95
Future Revenue Potential Will Advance With Deepening Market Penetration and Pipeline Progress
Key Takeaways Widening market adoption and evolving treatment guidelines for ARCALYST are driving sustained revenue growth and strengthening the company's competitive stance. Diverse pipeline advances and strong financial discipline support long-term earnings growth, operational leverage, and continued innovation investment.Read more
135
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
AN
US$55.88
17.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
25.04% p.a.
Profit Margin
13.84%
Future PE
36.02x
Price in 2029
US$68.63
ARCALYST Uptake And Pipeline Progress Will Expand Rare Markets
Key Takeaways Strong ARCALYST adoption and patient access improvements could drive revenue and margin growth well beyond current market expectations. Diversified pipeline and digital innovation position Kiniksa for sustained growth and reduced reliance on any single product.Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$62
25.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
30.9% p.a.
Profit Margin
18.57%
Future PE
26.53x
Price in 2028
US$76.73
Trending Discussion
Recently Updated Narratives
AN
KNSA: Pericarditis Market Opportunity And Single-Drug Concentration Will Shape Outlook
Fair Value: US$50 7.4% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KNSA: Recurrent Pericarditis Opportunity And Strong Prescriber Adoption Will Drive Future Upside
Fair Value: US$55.88 17.1% undervalued intrinsic discount
21 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KNSA: Earnings Upside Will Be Driven By Next Generation Candidate Potential
Fair Value: US$62 25.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kiniksa Pharmaceuticals International, plc Key Details
About KNSA
- Founded
- 2015
- Employees
- 366
- CEO
- WebsiteView website
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
